Biosimilar drug makers settle IP spat over arthritis drug Humira


German drug company Fresenius Kadi has resolved a patent case brought by Korean drug company Samsung Bioepis over a biosimilar of top selling arthritis drug Humira.
For information on rights and reprints, contact subscriptions@lawyerly.com.au